Protease Inhibitors Prevent Plasminogen-Mediated, But Not Pemphigus Vulgaris-Induced, Acantholysis in Human Epidermis
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 378874357 | ||
| 003 | CHVBK | ||
| 005 | 20180305123417.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 161128e20030220xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1515/BC.2003.035 |2 doi |
| 035 | |a (NATIONALLICENCE)gruyter-10.1515/BC.2003.035 | ||
| 245 | 0 | 0 | |a Protease Inhibitors Prevent Plasminogen-Mediated, But Not Pemphigus Vulgaris-Induced, Acantholysis in Human Epidermis |h [Elektronische Daten] |c [T. Schuh, R. Besch, E. Braungart, M.J. Flaig, K. Douwes, C.A. Sander, V. Magdolen, C. Probst, K. Wosikowski, K. Degitz] |
| 520 | 3 | |a Pemphigus is an autoimmune blistering disease of the skin and mucous membranes. It is caused by autoantibodies directed against desmosomes, which are the principal adhesion structures between epidermal keratinocytes. Binding of autoantibodies leads to the destruction of desmosomes resulting in the loss of cell-cell adhesion (acantholysis) and epidermal blisters. The plasminogen activator system has been implicated as a proteolytic effector in pemphigus. We have tested inhibitors of the plasminogen activator system with regard to their potential to prevent pemphigusinduced cutaneous pathology. In a human split skin culture system, IgG preparations of sera from pemphigus vulgaris patients caused histopathologic changes (acantholysis) similar to those observed in the original pemphigus disease. All inhibitors that were tested (active site inhibitors directed against uPA, tPA, and/or plasmin; antibodies neutralizing the enzymatic activity of uPA or tPA; substances interfering with the binding of uPA to its specific cell surface receptor uPAR) failed to prevent pemphigus vulgaris IgG-mediated acantholysis. Plasminogen mediated acantholysis, however, was effectively antagonized by the synthetic active site serine protease inhibitor WX-UK1 or by p-aminomethylbenzoic acid. Our data argue against applying anti-plasminogen activator/anti-plasmin strategies in the management of pemphigus. | |
| 540 | |a Copyright © 2003 by Walter de Gruyter GmbH & Co. KG | ||
| 690 | 7 | |a Biochemistry |2 nationallicence | |
| 690 | 7 | |a Molecular biology |2 nationallicence | |
| 690 | 7 | |a Cellular biology |2 nationallicence | |
| 700 | 1 | |a Schuh |D T. |4 aut | |
| 700 | 1 | |a Besch |D R. |4 aut | |
| 700 | 1 | |a Braungart |D E. |4 aut | |
| 700 | 1 | |a Flaig |D M.J. |4 aut | |
| 700 | 1 | |a Douwes |D K. |4 aut | |
| 700 | 1 | |a Sander |D C.A. |4 aut | |
| 700 | 1 | |a Magdolen |D V. |4 aut | |
| 700 | 1 | |a Probst |D C. |4 aut | |
| 700 | 1 | |a Wosikowski |D K. |4 aut | |
| 700 | 1 | |a Degitz |D K. |4 aut | |
| 773 | 0 | |t Biological Chemistry |d Walter de Gruyter |g 384/2(2003-02-20), 311-315 |x 1431-6730 |q 384:2<311 |1 2003 |2 384 |o bchm | |
| 856 | 4 | 0 | |u https://doi.org/10.1515/BC.2003.035 |q text/html |z Onlinezugriff via DOI |
| 908 | |D 1 |a research article |2 jats | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1515/BC.2003.035 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Schuh |D T. |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Besch |D R. |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Braungart |D E. |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Flaig |D M.J. |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Douwes |D K. |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Sander |D C.A. |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Magdolen |D V. |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Probst |D C. |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Wosikowski |D K. |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Degitz |D K. |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Biological Chemistry |d Walter de Gruyter |g 384/2(2003-02-20), 311-315 |x 1431-6730 |q 384:2<311 |1 2003 |2 384 |o bchm | ||
| 900 | 7 | |b CC0 |u http://creativecommons.org/publicdomain/zero/1.0 |2 nationallicence | |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-gruyter | ||